Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU's CHMP Delays Decision On Actos, Restricts Use Of An NSAID And Cytoprotective

This article was originally published in The Pink Sheet Daily

Executive Summary

Europe's top regulatory advisory panel wants further analysis of Actos' link with bladder cancer, but recommends limiting indications for the NSAID nimesulide and adding contraindications for the cytoprotective dexrazoxane.
Advertisement

Related Content

Deals Of The Week: Pfizer Management Updates Thoughts On Split
Actos To Get Bladder Cancer Warnings In Europe And A Chance At A Rebound
Actos To Get Bladder Cancer Warnings In Europe And A Chance At A Rebound
Newly Funded Health Records Database Will Boost Japan's Pharmacovigilance
Proliferation Of New Diabetes Drugs Prompts Call For Comparative Effectiveness Trials
Actos Gets Stronger Bladder Cancer Warning, But Escapes Black Box
First France, Now Germany Pulls Takeda's Actos For New Patients On Bladder Cancer Risk
First France, Now Germany Pulls Takeda's Actos For New Patients On Bladder Cancer Risk
Takeda Boosts European, Emerging Markets Footprint With $13.6B Nycomed Buy
EU Suspends Avandia; Pressure On Open Decision-Making May Stay

Topics

Advertisement
UsernamePublicRestriction

Register

PS072419

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel